Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Generics
Canada-based Bausch Health, and its gastroenterology business Salix Pharmaceuticals, announced that the US Court of Appeals for the Federal Circuit announced a positive ruling on its patent dispute with Norwich Pharmaceuticals. 12 April 2024
Pharmaceutical
USA-based Nectero Medical has raised $96 million in a Series D financing round led by Norwest Venture Partners, with significant investments also from Boston Scientific, BioStar Capital and others. 12 April 2024
Biotechnology
US mRNA medicines company Moderna has paused its efforts to build a manufacturing facility in Kenya while it determines future demand for mRNA vaccines on the African continent. 12 April 2024
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) recommends Kymriah (tisagenlecleucel) as a treatment option for children and young adults in England and Wales with acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. 12 April 2024
Biotechnology
US biotech Century Therapeutics has announced three news updates in a single day. 11 April 2024
Biotechnology
Adding another Big Pharma to its licensing deals, US biotech Arvinas today announced it has entered an exclusive strategic license agreement with Swiss pharma giant Novartis. 11 April 2024
Biotechnology
Shares of US biotech Moderna jumped to nearly $108 on Wednesday after the firm revealed encouraging data for its cancer vaccine, mRNA-4157. 11 April 2024
Biotechnology
Singapore-based contract research organization (CRO) Novotech has released an expert report, Acute Myeloid Leukemia - Global Clinical Trial Landscape, offering critical data-backed analysis of the latest developments in acute myeloid leukemia (AML) research. 11 April 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending Aquipta (atogepant). 11 April 2024
Biotechnology
French pharma major Sanofi is to close Kiadis, the Dutch natural killer (NK) cell company that it acquired in 2020 for $357 million. 11 April 2024
Biotechnology
Shares of Seattle, USA-based biotech Alpine Immune Sciences 20% on a takeover rumor by Bloomberg, and leapt a further 36% pre-market to $64.10 when the speculation was confirmed. 11 April 2024
Pharmaceutical
Data from the RESMAIN study of Kinselby (resminostat) have been presented at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasadena, California, USA. 11 April 2024
Pharmaceutical
The European Parliament has formally adopted new pharmaceutical legislation, including proposals for a new directive and a new regulation. 11 April 2024
Biotechnology
US clinical-stage biotech Rallybio Corporation saw its shares leap 76% to $2.87 pre-market today, after it revealed a collaboration with healthcare giant Johnson & Johnson. 11 April 2024
Biotechnology
The US Department of Justice (DoJ) says it has filed a complaint under the False Claims Act (FCA) against Regeneron. 11 April 2024
Biotechnology
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics for the design of a Phase IIIb trial of NurOwn (MSC-NTF cells). 10 April 2024
Biotechnology
Los Angeles, USA-based TORL BioTherapeutics, a biotech focused on discovering and developing antibody-based immunotherapies, has closed an oversubscribed $158 million Series B-2 financing. 10 April 2024
Pharmaceutical
Affecting one in 19 women, polycystic ovary syndrome (PCOS) remains understudied, with no dedicated treatments. Surprisingly, new diabetes and weight loss drugs may help. 10 April 2024
Pharmaceutical
A private share placement is set to land Massachusetts, USA-based Acrivon Therapeutics with an additional $130 million to fund its oncology research. 10 April 2024
Pharmaceutical
Keen to take French pharm major Sanofi head-on, the Serum Institute of India (SII) is to scale up supplies to fulfil India's entire annual demand for injectable inactivated poliomyelitis vaccines (IPV). 10 April 2024
All news
Pharmaceutical
al rule on April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) programs.
New Medicare proposals will not cover obesity drugs
April 4, 2025 5 April 2025
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Biotechnology
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults living with immunoglobulin G4-related disease (IgG4-RD), the drug’s developer, Amgen announced yesterday. 4 April 2025
Biotechnology
US biotech MoonLake Immunotherapeutics has entered into an agreement with Hercules Capital for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake’s strategy and funding needs. 4 April 2025
Biotechnology
Struggling US genomic medicines company Sangamo Therapeutics has been offered a lifeline via a licensing deal with pharma major Eli Lilly, sending its share up 24% to $0.77. 4 April 2025
Biosimilars
An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary of Biocon. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Biotechnology
Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. 4 April 2025
Biotechnology
A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. 4 April 2025
Biotechnology
UK pharma major AstraZeneca today reported extended approvals in Europe for two of its cancer drugs: Imfinzi (durvalumab) and Enhertu (trastuzumab deruxtecan). 4 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Biotechnology
US regenerative cell therapy specialist Neurona Therapeutics has announced the successful completion of an upsized and oversubscribed $102 million financing. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Biotechnology
US biotech BioMarin Pharmaceutical yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically-significant lowering in blood phenylalanine( Phe) levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. 3 April 2025
Biotechnology
Sino-American biotech BeiGene today revealed it intends to discontinue its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. 3 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze